专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

US20080014183A1 Anticancer Agent Containing Dendritic Cell Having Rna Virus Transferred Thereinto 有权
标题翻译：含有转移Rna病毒的树突状细胞的抗癌剂
公开(公告)号：US20080014183A1
公开(公告)日：2008-01-17
申请号：US11630532
申请日：2005-04-28
申请人： Shinji Okano , Yoshikazu Yonemitsu , Katsuo Sueishi , Satoko Shibata , Mamoru Hasegawa , Haruhiko Kondo
发明人： Shinji Okano , Yoshikazu Yonemitsu , Katsuo Sueishi , Satoko Shibata , Mamoru Hasegawa , Haruhiko Kondo
IPC分类号： A61K48/00
CPC分类号： A61K35/76 , A61K35/768 , A61K38/179 , A61K38/215 , A61K2039/5154 , C12N2760/18832 , C12N2760/18871
摘要： The present invention provides anticancer agents comprising dendritic cells introduced with RNA viruses. The present invention also provides methods for producing anticancer agents, which comprise the step of preparing dendritic cells introduced with RNA viruses. The present invention also provides methods for treating cancers using dendritic cells introduced with RNA viruses. The present invention provides effective methods for treating cancers, which use RNA viruses and dendritic cells in combination
摘要翻译：本发明提供包含引入RNA病毒的树突状细胞的抗癌剂。本发明还提供了制备抗癌剂的方法，其包括制备引入RNA病毒的树突状细胞的步骤。本发明还提供了用RNA病毒引入的树突状细胞治疗癌症的方法。本发明提供了组合使用RNA病毒和树突状细胞的治疗癌症的有效方法

62. 发明授权

US07144579B2 Paramyxoviruses comprising modified transcription start sequence 失效
标题翻译：副粘病毒包括修饰的转录起始序列
公开(公告)号：US07144579B2
公开(公告)日：2006-12-05
申请号：US09979908
申请日：2001-11-28
申请人： Yoshiyuki Nagai , Atsushi Kato , Mamoru Hasegawa , Makoto Inoue
发明人： Yoshiyuki Nagai , Atsushi Kato , Mamoru Hasegawa , Makoto Inoue
IPC分类号： C07H19/00 , C12N15/63 , C12N15/66 , A61K39/12 , A61K39/155
CPC分类号： C07K14/005 , A61K48/00 , C12N15/86 , C12N2760/18822 , C12N2760/18843
摘要： The present invention provides virus vectors of the family Paramyxoviridae in which the transcription start (S) sequence has been modified so as to modify the expression of genes located downstream thereof, a method for producing the vectors, and uses thereof. By measuring the transcription initiation efficiency of the S sequence of each gene carried by Sendai viruses (SeV), it was clarified that the S sequence of F gene has a significantly lower ability to promote transcription than the other three S sequences. When the S sequence of the F gene of wild type Sendai virus was substituted by the S sequence of the P/M/HN gene-type showing a high transcription initiation efficiency, the F gene of the resultant Sendai virus mutant and genes located downstream thereof show elevated expression levels. It was also revealed that this mutant proliferates more quickly than the wild type. The vectors of this invention are useful in elevating the expression of foreign genes and producing pharmaceutical compositions and vaccines. Furthermore, by lowering virus gene expression from virus vectors, it is possible to suppress transcription and/or replication and reduce cytotoxicity of the vector genome.
摘要翻译：本发明提供了副粘病毒科的病毒载体，其中已经修饰了转录起始（S）序列，以便修饰其下游的基因的表达，生成载体的方法及其用途。通过测量仙台病毒（SeV）携带的每个基因的S序列的转录起始效率，阐明了F基因的S序列比其他三个S序列具有显着较低的促进转录能力。当野生型仙台病毒的F基因的S序列被显示高转录起始效率的P / M / HN基因型的S序列取代时，得到的仙台病毒突变体的F基因和位于其下游的基因显示升高的表达水平。还显示，该突变体比野生型增殖更快。本发明的载体可用于提高外源基因的表达并产生药物组合物和疫苗。此外，通过降低来自病毒载体的病毒基因表达，可以抑制转录和/或复制并降低载体基因组的细胞毒性。

63. 发明授权

US07101685B2 Recombinant Sendai virus 有权
标题翻译：重庆仙台病毒
公开(公告)号：US07101685B2
公开(公告)日：2006-09-05
申请号：US09728207
申请日：2000-12-01
申请人： Yoshiyuki Nagai , Atsushi Kato , Fukashi Murai , Tsuneaki Sakata , Mamoru Hasegawa , Tatsuo Shioda
发明人： Yoshiyuki Nagai , Atsushi Kato , Fukashi Murai , Tsuneaki Sakata , Mamoru Hasegawa , Tatsuo Shioda
IPC分类号： C12N15/09 , A61K39/155
CPC分类号： C07K14/005 , C12N7/00 , C12N15/86 , C12N2760/18843 , C12N2760/18852
摘要： A method for generating Sendai virus particles by transfecting the Sendai virus genome to a host expressing all genes for the initial viral replication has been developed, enabling the genetic manipulation of Sendai virus and effective utilization of said virus as the vector.
摘要翻译：已经开发了通过将仙台病毒基因组转染到表达用于初始病毒复制的所有基因的宿主来产生仙台病毒颗粒的方法，使得能够对仙台病毒进行遗传操作并有效利用所述病毒作为载体。

64. 发明申请

US20060057139A1 Process for producing humanized chimera antibody 审中-公开
公开(公告)号：US20060057139A1
公开(公告)日：2006-03-16
申请号：US11228293
申请日：2005-10-25
申请人： Kenya Shitara , Nobuo Hanai , Mamoru Hasegawa , Hiromasa Miyaji , Yoshihisa Kuwana
发明人： Kenya Shitara , Nobuo Hanai , Mamoru Hasegawa , Hiromasa Miyaji , Yoshihisa Kuwana
IPC分类号： A61K39/395 , C07H21/04 , C12P21/06 , C12N5/06
CPC分类号： C07K16/3084 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K16/462 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/02
摘要： A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.

65. 发明申请

US20050221292A1 Vectors with modified protease-dependent tropism 有权
标题翻译：具有修饰的蛋白酶依赖性向量的载体
公开(公告)号：US20050221292A1
公开(公告)日：2005-10-06
申请号：US10513094
申请日：2003-04-30
申请人： Hiroaki Kinoh , Makoto Inoue , Yasuji Ueda , Akihiro Iida , Mamoru Hasegawa , Masanori Kobayashi
发明人： Hiroaki Kinoh , Makoto Inoue , Yasuji Ueda , Akihiro Iida , Mamoru Hasegawa , Masanori Kobayashi
IPC分类号： A61K38/00 , A61K48/00 , A61P35/00 , C07K14/115 , C12N15/45 , C12N15/86 , C12Q1/70 , C12Q1/68
CPC分类号： C07K14/005 , A61K38/00 , A61K48/00 , C07K2319/50 , C12N15/86 , C12N2760/18022 , C12N2760/18822 , C12N2760/18843 , C12N2800/30
摘要： The present invention provides cell fusogenic vectors having replicative ability, whose protease-dependent tropism has been modified. M gene-deficient viral vectors encoding modified F proteins, in which the cleavage site of the F protein of paramyxovirus is modified to be cleaved by different proteases, were produced. In cells transfected with these vectors, the genomic RNA present in the vectors is replicated, and cell fusogenic infection spreads to neighboring cells depending on the presence of other proteases; however, no viral particles are released. The vectors of this invention, encoding the F proteins which are cleaved by proteases whose activity is enhanced in cancer, show cancer growth suppressive effect in vivo.
摘要翻译：本发明提供具有复制能力的细胞融合载体，其蛋白酶依赖性向性已被修饰。产生编码修饰的F蛋白的M基因缺陷型病毒载体，其中修饰了被不同蛋白酶切割的副粘病毒的F蛋白的切割位点。在用这些载体转染的细胞中，载体中存在的基因组RNA被复制，并且根据其它蛋白酶的存在，细胞融合感染扩散到相邻细胞; 然而，没有病毒颗粒被释放。本发明的编码由蛋白酶切割的F蛋白的载体，其活性在癌症中增强，在体内显示出癌症生长抑制作用。

66. 发明授权

US06759231B2 Phage with nuclear localization signal 失效
标题翻译：噬菌体与核定位信号
公开(公告)号：US06759231B2
公开(公告)日：2004-07-06
申请号：US09844813
申请日：2001-04-27
申请人： Mahito Nakanishi , Emi Nagoshi , Teruo Akuta , Katsuo Takeda , Mamoru Hasegawa
发明人： Mahito Nakanishi , Emi Nagoshi , Teruo Akuta , Katsuo Takeda , Mamoru Hasegawa
IPC分类号： C12N120
CPC分类号： C12N15/1037 , C12N15/85 , C12N15/86 , C12N15/87 , C12N2795/10343
摘要： A &lgr; phage with a nuclear localization signal has been obtained by constructing a vector capable of expressing a fused protein between a gpD protein constituting the head of a &lgr; phage and a nuclear localization signal sequence, transforming Escherichia coli with this vector, and propagating a mutant &lgr; phage which cannot express the gpD protein in E. coli in this transformant. It has been confirmed that the resulting &lgr; phage is capable of packaging &lgr; phage DNAs of 80% and 100% genome sizes. After further confirming that the nuclear localization signal exposed on the outside of the head of this phage, this phage has been microinjected into cells to analyze its nuclear localization activity. Thus, it has been clarified that this phage has a nuclear localization activity.
摘要翻译：已经通过构建能够在构成λ噬菌体的头部的gpD蛋白质和核定位信号序列之间表达融合蛋白质的载体，用该载体转化大肠杆菌并扩增突变体来获得具有核定位信号的λ噬菌体 λ噬菌体在该转化体中不能在大肠杆菌中表达gpD蛋白。已经证实所得的λ噬菌体能够包装80％和100％基因组大小的λ噬菌体DNA。在进一步证实核定位信号暴露在该噬菌体头部的外部时，该噬菌体已被微量注入细胞以分析其核定位活性。因此，已经澄清这种噬菌体具有核定位活动。

67. 发明授权

US06716608B1 Artificial chromosome 失效
标题翻译：人造染色体
公开(公告)号：US06716608B1
公开(公告)日：2004-04-06
申请号：US09254947
申请日：2000-03-13
申请人： Fuyuki Ishikawa , Mamoru Hasegawa
发明人： Fuyuki Ishikawa , Mamoru Hasegawa
IPC分类号： C12P1934
CPC分类号： C12N9/1241 , C12N15/81 , C12N15/85 , C12N2800/206 , C12N2830/002 , C12N2830/702
摘要： An artificial mammalian chromosome, more specifically, a clone containing a mammalian centromere sequence and a DNA replication origin with mammalian telomere sequences added to both ends of the clone, is provided by preparing a CEPH artificial yeast chromosome library containing a human genome, identifying clones having a repetitive human alphoid sequence from this library, and further preparing a yeast strain in which mammalian telomere sequences are added to the ends of its chromosome.
摘要翻译：通过制备含有人类基因组的CEPH人工酵母染色体文库，鉴定了克隆含有人源哺乳动物染色体，更具体地，含有哺乳动物着丝粒序列和DNA复制起点的克隆，其中所述克隆含有哺乳动物端粒序列，来自该文库的重复的人类亚型序列，并进一步制备其中将哺乳动物端粒序列加入其染色体的末端的酵母菌株。

68. 发明授权

US06225459B1 TEC promoter 失效
公开(公告)号：US06225459B1
公开(公告)日：2001-05-01
申请号：US09142529
申请日：1999-08-12
申请人： Hiroyuki Mano , Tsuneaki Sakata , Mamoru Hasegawa
发明人： Hiroyuki Mano , Tsuneaki Sakata , Mamoru Hasegawa
IPC分类号： C07H2104
CPC分类号： C12N9/1205 , C12N15/85 , C12N2830/00 , C12N2830/85
摘要： The present invention provides a DNA having promoter activity of Tec tyrosine kinase and a vector having incorporated within it the promoter to thereby enable a high level expression of an exogenous gene in hematopoietic stem cells and hepatic cells.

69. 发明授权

US5866692A Process for producing humanized chimera antibody 失效
公开(公告)号：US5866692A
公开(公告)日：1999-02-02
申请号：US454680
申请日：1995-05-31
申请人： Kenya Shitara , Nobuo Hanai , Mamoru Hasegawa , Hiromasa Miyaji , Yoshihisa Kuwana
发明人： Kenya Shitara , Nobuo Hanai , Mamoru Hasegawa , Hiromasa Miyaji , Yoshihisa Kuwana
IPC分类号： A61K36/00 , A61K38/00 , A61P35/00 , C07K7/06 , C07K7/08 , C07K14/00 , C07K16/00 , C07K16/18 , C07K16/30 , C07K16/32 , C07K16/46 , C07K19/00 , C12N5/10 , C12N15/00 , C12N15/09 , C12N15/12 , C12N15/13 , C12N15/62 , C12P21/08 , C12R1/91 , C12N15/11
CPC分类号： C07K16/3084 , C07K16/18 , C07K16/462 , A61K2039/505 , A61K38/00 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/02
摘要： A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of said humanized chimera antibody, are disclosed.

70. 发明授权

US5830470A Humanized antibodies to ganglioside GM.sub.2 失效
公开(公告)号：US5830470A
公开(公告)日：1998-11-03
申请号：US116778
申请日：1993-09-07
申请人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
发明人： Kazuyasu Nakamura , Masamichi Koike , Kenya Shitara , Nobuo Hanai , Yoshihisa Kuwana , Mamoru Hasegawa
IPC分类号： A61K38/00 , C07K16/18 , C07K16/46 , C12N1/21 , C12N15/13 , C12P21/08 , A61K39/395 , C07H21/04 , C12P21/04
CPC分类号： C07K16/3084 , C07K16/18 , C07K16/464 , A61K38/00 , C07K2317/24 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/035 , Y10S530/867
摘要： Chimeric human antibody expression vectors are constructed by inserting the antibody heavy chain variable region-encoding cDNA and antibody light chain variable region-encoding cDNA isolated from hybridomas producing a mouse or rat monoclonal antibody reacting with the ganglioside GM.sub.2 respectively into an expression vector for use in animal cells which contains the human antibody heavy chain constant region- or human antibody light chain constant region-encoding cDNA. The expression vectors are introduced into animal cells and the transformant thus obtained is cultured for the production of a chimeric human antibody reacting with the ganglioside GM.sub.2. In contrast to mouse monoclonal antibodies, the chimeric human antibodies of the invention will not cause anti-mouse immunoglobulin antibody production in the patient's body but shows a prolonged blood half-life, with a reduced frequency of adverse effects, so that it can be expected to be superior to mouse monoclonal antibodies in the efficacy in the treatment of human cancer, for instance.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式